Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US6326205

Title:Methods for use of Mpl ligands with primitive human stem cells
Inventors:Murray, Lesley J.; San Jose, CA, USA
Young, Judy C.; San Carlos, CA, USA
Summary:This invention introduces novel uses of myeloproliferative leukemia receptor ligands (mpl) for the stimulation of stem cells. The invention relates to mpls such as thrombopoietin which act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and the ability to give rise to all hematopoietic cell lineages. The thrombopoietin described herein supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34+ and CD34+ sub-populations, namely, of CD34+ Lin-, CD34+ Thy-1+ Lin-, and CD34+ Lin- Rh123lo, while also stimulating quiescent human stem cells to begin cycling. Therapeutic applications of such mpls include the expansion of primitive stem cells for the restoration of hematopoietic capabilities and for providing modified human stem cells in gene therapy.
Abstract:Myeloproliferative leukemia receptor (mpl) ligands, such as thrombopoietin, act on a primitive subpopulation of human stem cells having the characteristics of self-renewal and ability to give rise to all hematopoietic cell lineages. Thrombopoietin supports both megakaryocytic differentiation and primitive progenitor cell expansion of CD34.sup.+ and CD34.sup.+ sub-populations (CD34.sup.+ Lin.sup.-, CD34.sup.+ Thy-1.sup.+ Lin.sup.-, and CD34.sup.+ Lin.sup.- Rh123.sup.lo). Thrombopoietin also stimulated quiescent human stem cells to begin cycling. Thus, mpl ligands are useful for expanding primitive stem cells for restoration of hematopoietic capabilities and for providing modified human stem cells for gene therapy applications.
US Patent Website:Click Here for Full Text of Patent
Title Number:US6326205
Application Number:US1999000328188
Date Filed:08/06/1999
Date Published:04/12/2001
Assignee:SyStemix, Inc., Palo Alto, CA, USA


 
Copyright © 2007 The Institute for Cellular Medicine  10/6/2024